Cardinal Health stock steadies around $236 as earnings beat and FY 2027 guidance support valuation

Cardinal Health Inc. (ISIN US14149Y1082) stock is trading close to the mid-$230s on August 18, 2026, with investors weighing a recent earnings beat against the company’s updated guidance and valuation.

Per recent market data as of August 18, 2026, Cardinal Health shares are quoted at $235.94, modestly above the prior close of $235.68, while the stock’s market capitalization stands close to $54.8 billion. One live quote snapshot also shows the shares closing at $235.94 on August 17, 2026, up 0.33% on the day.

Shares hold in upper trading range

Recent price data indicate that Cardinal Health stock closed at $235.68 on August 17, 2026, with extended trading slightly softer at $235.38 early on August 18, 2026. A consolidated news and quote overview lists the $235.68 close with a modest gain of $0.51, equal to a 0.22% increase, underscoring a steady, rather than volatile, trading pattern.

Intraday data from August 18, 2026 show Cardinal Health shares reaching a session high of $238.94 and a low of $233.85, with the current price of $235.98 sitting 0.9% above the low and 1.2% below the high. A trading overview also reports volume at 1.8 million shares for the session versus an average daily volume of 2.21 million shares, suggesting liquidity remains healthy even as the stock consolidates in a narrow band.

For investors, the broader context matters: Cardinal Health has traded between a twelve-month low of $145.87 and a twelve-month high of $258.30, according to a recent institutional-activity snapshot. That overview indicates the stock’s 50-day simple moving average at $230.93 and 200-day simple moving average at $217.34, confirming that the current $235–$236 range is above key medium- and longer-term trend levels.

Earnings beat and guidance underpin the story

The latest reported quarter is central to the current narrative. Cardinal Health most recently released earnings for a quarter ended in 2026, with results published on August 11. An earnings summary points to earnings per share (EPS) of $2.91 for the quarter, ahead of analysts’ consensus estimates of $2.42. That $0.49 positive surprise represents a beat of roughly 20.2% versus expectations, a material gap that often shapes sentiment around the stock.

Revenue performance was somewhat more mixed. The company generated $63.67 billion in sales during the quarter, compared with analyst expectations of $65.15 billion. The same summary notes that revenue still rose 5.8% year-over-year, evidencing solid top-line growth even though the figure fell $1.48 billion short of the consensus estimate. For comparison, the company earned $2.08 EPS in the same quarter of the prior year, meaning EPS expanded by $0.83, or 39.9%, on an annual basis.

Cardinal Health’s profitability metrics are complex but important for investors to track. Recent data show the company posting a net margin of 0.67%, reflecting the razor-thin margins typical in pharmaceutical distribution. The same report also cites a negative return on equity of 98.53%, a figure influenced by accounting items like goodwill and intangible impairments as well as the company’s capital structure. For shareholders, the combination of low net margin and a complex equity base underscores why EPS guidance and cash returns tend to command attention.

Looking ahead, Cardinal Health has set its fiscal 2027 EPS guidance in a range of $12.40 to $12.60. Guidance commentary indicates that analysts on average forecast EPS of $12.55 for the current fiscal year, effectively aligning consensus with the midpoint of management’s range. That alignment tends to reduce forecast dispersion and can support valuation stability when the broader market is uncertain.

Dividend investors also have fresh information to digest. Cardinal Health recently declared a quarterly dividend of $0.5158 per share, with a record date of October 1, 2026 and a payment date of October 15, 2026. Dividend detail suggests the annualized payout stands at $2.06 per share, implying a yield close to 0.9% at recent prices and a payout ratio of 28.49%. A separate dividend overview lists the current yield at 0.87%, consistent with this range. That dividend-focused snapshot reinforces the signal that management is using a moderate portion of earnings to return cash to shareholders.

Institutional interest and valuation context

Institutional flows add another layer to the story. Several recent filings show asset managers initiating or expanding positions in Cardinal Health during 2026, with one filing highlighting a new stake and another pointing to fresh share purchases. A report on one asset manager’s activity notes that shares opened at $235.68 on August 18, 2026 and reiterates the stock’s twelve-month trading band between $145.87 and $258.30, along with the moving-average levels mentioned earlier.

Consensus sentiment among equity analysts is moderately constructive. Several coverage snapshots indicate that the stock currently carries a consensus rating described as “Moderate Buy”, with an average price target of $265.93. One rating and target overview cites the same $265.93 consensus target, implying upside of about 12.7% from the current $235.98 price level if those targets are realized.

Current valuation ratios provide a numerical frame for that view. Cardinal Health stock is reported to trade at a price-to-earnings ratio of 32.52 based on recent data, with a dividend yield of 0.87%. A compact valuation snapshot couples those metrics with the $54.81 billion market capitalization figure, helping investors compare the company against other large-cap healthcare distributors. Taken together with the EPS guidance of $12.40–$12.60, the current P/E suggests the market is pricing in relatively steady earnings growth and moderate risk.

Beyond the numbers, operational developments are contributing to Cardinal Health’s long-term positioning. A recent regional business report notes that the company’s new drugstore hub near the Rickenbacker corridor supported a record fiscal 2026 sales performance, with the company posting a quarter-trillion dollars in annual revenue. Coverage of the fiscal 2026 results frames this record sales figure as part of a broader logistics and distribution expansion strategy.

Drug distribution and services backbone

Cardinal Health operates as a nationwide drug distributor and provider of services to pharmacies, healthcare providers and manufacturers, making it a critical link in the pharmaceutical supply chain. A concise company profile describes the business as a large-scale distributor with complementary services that help healthcare organizations manage inventory, compliance and cost pressures.

A representative offering in Cardinal Health’s portfolio is its suite of pharmacy services and distribution solutions for retail chains and hospital systems. These services typically combine bulk drug purchasing, logistics, inventory management and data analytics to ensure that pharmacies can maintain appropriate stock levels and reduce waste. While specific product names vary by client and contract, the common thread is an integrated platform that aims to make medication delivery more reliable and efficient across the United States.

From an investor’s point of view, this business model translates into very high revenue figures and small per-unit margins, with profitability driven by scale, operational efficiency and disciplined risk management. The recent quarter’s $63.67 billion in revenue alongside a 0.67% net margin underscores that dynamic: volume and efficiency matter as much as price, and incremental improvements at the margin can have outsized effects on net income and EPS over time.

Cardinal Health stock and market perspective

Cardinal Health stock is listed on the New York Stock Exchange under the ticker CAH and trades in U.S. dollars. Recent quote snapshots place the shares at $235.98 during the August 18, 2026 session, following a previous close of $235.68 on August 17, 2026 and intraday moves between $233.85 and $238.94. Intraday data also highlight session volume of 1.8 million shares versus an average of 2.21 million, signaling active though not extreme trading interest.

Given the backdrop of an earnings beat, record fiscal 2026 sales and aligned EPS guidance for fiscal 2027, many investors will likely focus on how Cardinal Health balances margin stability, capital returns through dividends and potential share repurchases, and incremental growth from logistics and service expansions. With the stock trading above its key moving averages yet below its twelve-month high of $258.30, the shares currently sit in a zone that reflects both recent progress and the need for continued execution.

Read more

Further details on Cardinal Health stock, including full financial statements, segment breakdowns and risk disclosures, can be found on the company’s investor information pages and in its latest regulatory filings.

Cardinal Health distribution and pharmacy solutions

One representative area of Cardinal Health’s portfolio is its distribution and pharmacy solutions platform, which combines large-scale drug purchasing with logistics and data analytics to help pharmacies manage inventory, costs and patient access.

Cardinal Health stock price and key metrics

As of the close on August 17, 2026, Cardinal Health stock traded at $235.68 on the New York Stock Exchange, with recent intraday quotes around $235.98 on August 18, 2026 and a market capitalization reported close to $54.8 billion.

Fact box

Company: Cardinal Health Inc.

ISIN: US14149Y1082

Ticker: CAH

Exchange: NYSE

Price (as of August 17, 2026, 3:58 p.m. ET): $235.68 USD

Market cap: $54.81 billion (as of August 18, 2026)

Sector / Industry: Healthcare - Drug distribution and services

Index membership: S&P 500